Regulatory

Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo Rivalry

BioSpace

The FDA approved Eli Lilly's orforglipron--to be known as Foundayo--on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk's oral Wegovy.

Regulatory Metabolic & GLP-1 Read full story

pharminent April 1, 2026 (Last updated: April 1, 2026)

BioSpace

The FDA approved Eli Lilly’s orforglipron–to be known as Foundayo–on Wednesday, officially igniting what analysts believe will be a fierce rivalry with Novo Nordisk’s oral Wegovy.

Regulatory Metabolic & GLP-1 Read full story

Related Stories

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval

Pfizer’s Hympavzi secures FDA expanded indications for haemophilia

Biogen’s salanersen gains FDA breakthrough therapy designation for SMA

You May Have Missed

Alzecure enters collaboration and with Lilly for Alzheimer’s project

ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data

GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year

ADA: Lilly bests Novo again, takes GLP-1 pill Foundayo to FDA for diabetes approval